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Introduction: In breast cancer, distinct expression profiles of microRNAs (miRNAs) have been associated with
molecular subgroups and clinicopathological characteristics, implicating a diagnostic and prognostic role of
miRNAs. However, the biological functions of deregulated miRNAs in tumor progression are not yet completely
defined. In this study, we investigated the function of miR-18a in regulating breast cancer metastasis through the
hypoxia-inducible factor 1α (HIF1A)–dependent hypoxic response.
Methods: An orthotopic metastatic breast cancer xenograft model (MDA-MB-231 cells) was used to identify miRNAs
associated with spontaneous lung metastasis. The function of miR-18a in regulating HIF1A expression, as well as cellular
responses to hypoxia and metastasis, were then studied in vitro and in vivo by assessing ectopic miR-18a expression
or miR-18a inhibition. miRNA–mRNA interactions (AGO2 immunoprecipitation and 3′ untranslated region Luciferase
reporter assays), gene expression (quantitative PCR and microarray), cell migration and invasion, and cell growth
were assessed under normoxic or hypoxic conditions, complemented by orthotopic xenograft of tumor cells to
the mammary fat pad to investigate the effect of modulating miR-18a expression on primary tumor growth and
lung metastasis. Last, clinically relevant correlations between miR-18a, HIF1A, hypoxia-responsive gene expression
and distant metastasis–free survival (DMFS) were assessed using published expression array breast tumors data sets.
Results: miRNAs encoded by the MIR17HG gene were downregulated in lung metastases compared to primary
tumors. Ectopic expression of miR-18a, a MIR17HG family member, in a metastatic variant of MDA-MB-231 cells reduced
primary tumor growth and lung metastasis, whereas miR-18a inhibition in the parental cells promoted tumor growth
and lung metastasis. We identified HIF1A as a direct target of miR-18a. Modulating miR-18a expression significantly
affected hypoxic gene expression, cell invasiveness and sensitivity to anoikis and hypoxia in vitro in a HIF1A-dependent
manner. Analysis of previously published data revealed that higher expression of HIF1A and a panel of hypoxic genes is
associated with shorter DMFS interval in patients with basal-like breast tumors, and that, within this subtype, miR-18a
expression is inversely correlated with hypoxic gene expression. Together, these data support a role of miR-18a in
repressing distant metastasis through a HIF1A-dependent pathway.
Conclusions: The results of this study reveal a novel role for miR-18a in targeting HIF1A and repressing metastasis of
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MicroRNAs (miRNAs) play an important role in co-
ordinating spatial and temporal expression of proteins by
regulating mRNA translation and stability [1]. Deregulation
of miRNAs has been linked to tumor development and
progression, and a growing number of miRNAs have been
described as candidate oncogenes or tumor suppressors [2].
In breast cancer, distinct expression profiles of miRNAs
have been associated with specific molecular subtypes and
clinicopathological characteristics, implicating a diagnostic
and prognostic role of miRNAs [3-5]. However, the bio-
logical functions of the deregulated miRNAs in tumor
progression have not yet been completely defined.
One of the most frequently deregulated miRNA-encoding
genes in human cancer is the polycistronicMIR17HG gene,
which encodes six miRNAs (miR-17, miR-20a, miR-18a,
miR-19a, miR-19b and miR-92a) [6]. MIR17HG was ori-
ginally described as an oncomir because of its oncogenic
function in the hematological system, thyroid and lung
[7]. However, emerging evidence suggests that loss of
function ofMIR17HG might contribute to the development
and progression of other types of cancers, implicating a
tumor suppressor function. For example, loss of heterozy-
gosity at chromosome 13q31, where the human MIR17HG
gene is located, was detected in approximately 25% of
human breast tumors [8]. In addition, MIR17HG over-
expression was found to inhibit proliferation of luminal
breast cancer cells by targeting a steroid receptor coactiva-
tor (NCOA3), cyclin D1 (CCND1) and estrogen receptor α
(ESR1) [9-12]. Furthermore, distinct physiological func-
tions have been linked to the different miRNA members
encoded by the MIR17HG gene [10,13,14]. Therefore, to
gain a more complete understanding of the physiological
impact of MIR17HG deregulation in cancer, a detailed
investigation of each individual MIR17HG family member
in multiple types of tumor cells is required.
In this study, we discovered that, compared to parental
cells (MB231RN) or a subline derived from the primary
tumors (MB231RN-MFP), miRNAs encoded by MIR17HG
were downregulated in a MDA-MB-231 subline isolated
from spontaneous lung metastases (MB231RN-LM) and
generated from tumor cells orthotopically implanted in
the mammary fat pad. Functional studies of miR-18a, a
relatively understudied MIR17HG family member, revealed
a major role in limiting continuous tumor growth and
suppressing tumor metastasis, in part by direct regulation
of hypoxia-inducible factor 1α (HIF1A) activity. Analysis
of previously published expression data revealed that
higher expression of HIF1A and a panel of hypoxic genes
is associated with a shorter interval of distant metastasis–
free survival (DMFS) only in basal-like breast tumors.
Additionally, a significant inverse correlation between
miR-18a expression and hypoxic gene expression was
discovered in basal-like tumors. These data suggest thatdownregulation of miR-18a and concomitant upregulation
of HIF1A activity may be essential to promoting basal
breast cancer metastasis to distant organs, including the
lungs.
Material and methods
Cell culture and stable transfection
MDA-MB-231, MCF7 and MDA-MB-436 cells (American
Type Culture Collection, Manassas, VA, USA) were main-
tained in minimal essential medium supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal
bovine serum. To facilitate tumor imaging and tumor
cell isolation in vitro, MDA-MB-231 cells were stably
transfected with pEF-mRFP [15] and pReceiver-Lv151
(GeneCopoeia, Rockville, MD, USA). The transfected
cells that express red fluorescent protein (RFP) and
neomycin-resistant marker were designated MB231RN
and were used to derive other sublines used in this study.
To establish cells that constitutively express miR-18a, lung
metastatic variants of MDA-MB-231 (LM) cells were
transduced with pEZX-MR06 (GeneCopoeia), a lenti-
viral vector that encodes a miR-18a stem loop and green
fluorescent protein (GFP), and were sorted to obtain
GFP-positive cells (LM-miR-18a). Control cells were
transduced with pEZX-MR03 (GeneCopoeia) expressing
GFP only (LM-GFP). The miArrest miR-18a inhibitor
encoded by a lentiviral vector that coexpresses mCherry
(HmiR-AN0255-AM03; GeneCopoeia) was used to es-
tablish MDA-MB-231 sublines with low miR-18a activ-
ity (MB231-18aIN). Control cells were transduced with
pEZX-AM03 (GeneCopoeia) expressing mCherry only
(MB231-C). HIF1A knockdown was achieved by trans-
ducing MB231-C or MB231-18aIN cells with lentiviruses
expressing a short-hairpin RNA (shRNA) to HIF1A
(pLKO.1-HIF1AshRNA: NM_001530.x-1048s1c1; Open
Biosystems/GE Dharmacon, Lafayette, CO, USA).
Generating cell sublines from spontaneous lung metastases
and orthotopic primary tumors
MB231RN cells (5 × 105 cells/10 μl phosphate-buffered
saline) were surgically inoculated into the right inguinal
mammary glands of 4-week-old female NOD scid γ mice
(NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJ, hereinafter NSG; The
Jackson Laboratory, Bar Harbor, ME, USA). Unless
otherwise stated, primary tumors were resected in
survival surgery performed 4 weeks postinoculation.
The lungs were extracted 5 weeks after primary tumor
removal and examined for the presence of metastatic
loci that express RFP under a fluorescence microscope
(CFI60; Nikon Instruments, Melville, NY, USA). To estab-
lish the lung metastatic subline, lungs displaying metastases
were minced with blades, digested with 1 mg/ml collage-
nase type III (Worthington Biochemical, Lakewood, NJ,
USA) overnight at 37°C, pelleted (1,500 rpm, 5 minutes),
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medium (DMEM) and plated in gelatin-coated flasks
containing DMEM/F-12 medium (Life Technologies,
Carlsbad, CA, USA) supplemented with 10% fetal bo-
vine serum, 30% human foreskin fibroblast conditioned
medium, 100 U/ml penicillin, 100 μg/ml streptomycin,
10 mg/ml fungin (InvivoGen, San Diego, CA, USA) and
400 μg/ml neomycin. Cells obtained from three lungs
were pooled and designated the MB231RN-LM subline.
Primary tumors grown in mammary gland fat pads were
digested and subjected to culture to obtain the MB231RN-
MFP subline. The same experimental procedures were used
to generate MB231RN-CE-LM and MB231RN-CE-MFP
sublines derived from mice inoculated with a clonal ex-
pansion (CE) of a single colony from MB231RN cells
(MB231RN-CE). All animal studies adhered to proto-
cols approved by the Institutional Animal Care and
Use Committee of the University of Tennessee Health
Science Center.
Primary tumor growth and lung metastasis
To monitor primary tumor growth, mice were inspected
weekly by manual palpation for tumor appearance. Tumor
growth was monitored twice weekly using digital calipers.
Tumor volume was calculated as follows: Volume =
(Width2 × Length)/2. To examine lung metastases, pri-
mary tumors were either surgically removed 4 weeks
after inoculation or left intact as indicated, and the
lungs were extracted as described per experiment.
Metastatic foci of RFP-expressing cells located on the
dorsal surface of the left lung lobe were imaged and
counted using a fluorescence microscope at × 10 mag-
nification (CFI60; Nikon Instruments). The presence of
tumor cells in the left lobes was further confirmed by
hematoxylin and eosin (H&E) staining of formalin-fixed
lung sections (10 μm thick). In addition, the right lobes of
the lungs were digested to prepare DNA, which was
then subjected to quantitative PCR (qPCR) analysis
using primers specific for the human Alu sequences
(hAlu-qPCR), as described previously [16].
Quantitation of mRNA and miRNA expression by qPCR
Total RNA was prepared using TRIzol reagent (Life
Technologies). mRNAs and miRNAs were converted to
cDNA using iScript cDNA synthesis kits (Bio-Rad
Laboratories, Hercules, CA, USA) and the NCode™ miRNA
First-Strand cDNA Synthesis Kit (Life Technologies), re-
spectively. qPCR was performed on the CFX96™ Touch
Real-Time PCR Detection System using SYBR Green
Supermix (Bio-Rad Laboratories). mRNA and miRNA
expression data were normalized to β-actin (ACTB) or a
small nuclear ribonucleic acid (U6), respectively, using
the 2−ΔΔCt method. Primer sequences for mRNAs were
obtained from PrimerBank [17], and for miRNAs theywere designed according to the manufacturer’s instruc-
tions included with the NCode™ miRNA First-Strand
cDNA Synthesis Kit. The expression levels of unprocessed
transcript of MIR17HG (pri-MIR17HG) were examined
using the TaqMan Pri-miRNA assay (Life Technologies) as
described previously [16].HIF1α 3′-UTR luciferase reporter assay
Luciferase reporter containing the 3′ untranslated region
(3′-UTR) of HIF1A mRNA (HIF1A-3′-UTR-Luc, S809216;
SwitchGear Genomics, Carlsbad, CA, USA) and pSV-β-
galactosidase (Promega, Madison, WI, USA), along with
pEZX-MR06 (expressing miR-18a and GFP) or control
vector pEZX-MR03 (expressing GFP only), were trans-
fected to MDA-MB-231/DROSHA-shRNA cells [16]
using Lipofectamine 2000 reagent (Life Technologies)
according to the manufacturer’s instructions. The lucifer-
ase and β-galactosidase activities were determined at
48 hours posttransfection using the Luciferase and Β-Glo
Assay Systems (Promega), respectively. Reported luciferase
activities were normalized to β-galactosidase activities. The
Phusion Site-Directed Mutagenesis Kit (Thermo Scientific,
Asheville, NC, USA) and the following 5′-phosphorylated
primers were used to generate HIF1A-3′-UTR-Luc re-
porters with mutated or deleted miR-18a binding sites:
mutagenic primer, forward 5′-CATTTTAAAAAATGC
ggCgTTTTATTTATTTATT-3′ and reverse 5′-ATG CTA
CTGCAATGCAATGGTTTAAATAC-3′; deletion primer
forward 5′-TTTATTTATTTTTGGCTAGGGAGTTTAT
CC-3′ and reverse 5′-TTTTTAAAATGATGCTACTGC
AATGC-3′.AGO2 immunoprecipitation, immunoblotting and
enzyme-linked immunosorbent assay
Argonaute 2 (AGO2) immunoprecipitation was performed
as described previously [16]. For immunoblotting, whole-
cell lysates were prepared with radioimmunoprecipitation
assay buffer (Thermo Scientific), and nuclear extract
was prepared as described previously [18]. Cell lysates
were resolved in SDS-PAGE, transferred to polyvinylidene
fluoride membrane and immunoblotted with the following
antibodies: anti-HIF1A (Epitomics, Burlingame, CA, USA),
anti-TATA-binding protein (anti-TBP; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), anti-PFKFB3 (6-phos-
phofructo-2-kinase/fructose-2,6-biphosphatase-3; Cell
Signaling Technology, Danvers, MA, USA), anti-BHLHE40
(basic helix-loop-helix family, member e40; Abnova, Taipei,
Taiwan) and anti-GAPDH (glyceraldehyde-3-phosphate
dehydrogenase; EMD Millipore, Billerica, MA, USA). A
cell-based enzyme-linked immunosorbent assay (ELISA)
(KCB1935; R&D Systems, Minneapolis, MN, USA) that
measures total HIF1A protein in the context of whole cells
was used to quantify HIF1A protein levels.
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Cells (2 × 104 cells/0.5 ml/well) were plated onto control
membrane inserts with 8-μm pores or onto Matrigel-coated
membrane inserts (BD Biosciences, San Diego, CA, USA)
that were placed in 24-well chambers filled with 0.6 ml of
growth medium. Twenty-four hours after plating, cells
that remained on the upper surface of the membrane were
removed using cotton-tipped swabs, and cells that had mi-
grated to or invaded the lower surface of the membrane
were fixed with methanol, stained with 0.5% crystal violet
and counted under the microscope. The migration per-
centage was calculated as follows: Migration (%) = (Mean
number of cells invading through uncoated insert × 100)/
Mean number of cells seeded onto the regulator culture
surface. The invasion percentage was calculated as follows:
Invasion (%) = (Mean number of cells invading through
Matrigel insert membrane × 100)/Mean number of cells
migrating through control insert membrane.
Cell growth and viability assays
To examine cell growth, cells were plated at a density of
3 × 104 cells/2 ml/well (six-well dish) and counted daily.
To culture cells under lactic acidosis and hypoxic condi-
tions, cells were seeded into medium with 25 mM lactic
acid (pH 6.7) and incubated in a Galaxy 14S multigas
incubator supplemented with 2% O2 and 5% CO2. To
induce anoikis, cells (5 × 104/well) were seeded into
six-well dishes coated with polyhydroxyethylmethacrylate
(Sigma-Aldrich, St Louis, MO, USA) to prevent cell
attachment. Viable cells were counted using a trypan blue
exclusion assay.
Microarray analysis
To induce chemical hypoxia, cells were treated with
200 μM cobalt(II) chloride (CoCl2) for 4 hours. Total
RNA from two sets of independent experiments was
prepared using the RNeasy Mini Kit (QIAGEN, Valencia,
CA, USA) and submitted to the Center of Genomics
and Bioinformatics at the University of Tennessee
Health Science Center (Memphis, TN, USA) for label-
ing and hybridization to HT-12 expression BeadChips
(Illumina, Chicago, IL, USA). Hybridization signals were
processed using Illumina Genome Studio software for an-
notation, background subtraction, quantile normalization
and presence call filtering. The normalized hybridization
signals with intensity <40 were set to the flooring value of
40. GeneSpring GX software (Agilent Technologies, Santa
Clara, CA, USA) was used for statistical computing. The
cutoff parameters for differentially expressed genes
were false discovery rate (FDR) = 0.1 and fold change
(FC) ≥ 1.5. The differentially expressed genes were further
subjected to functional annotation and signaling pathway
mapping using QIAGEN’S Ingenuity Pathway Analysis
(IPA) (Redwood City, CA, USA). The expression array datahave been deposited in the Gene Expression Omnibus
(GEO) database [GEO:GSE45362].
Statistical analysis of correlation between miR-18a and
HIF1α expression in breast tumors
The expression data of breast tumor samples were re-
trieved from the GEO database [GEO:GSE19783, GEO:
GSE22220, GEO:GSE28884] or the Cancer Genome Atlas
(TCGA). Tumor samples were assigned to five subtypes
(luminal A, luminal B, Her2-enriched, basal-like and
normal-like) using the PAM50 classifier [19]. The cor-
relation between miR-18a and HIF1A expression was
analyzed using GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA). The association of HIF1A
and hypoxia-responsive genes with distant metastasis was
analyzed with the GOBO program (Gene expression-
based Outcome for Breast cancer Online) [20].
Results
Generation of MDA-MB-231 subline with high metastatic
potential
To identify miRNAs involved in breast cancer metastasis,
we generated a lung metastatic subline by using an ortho-
tropic metastatic mouse model of basal-like breast cancer
MDA-MB-231 cells. MDA-MB-231 cells that express RFP
and the neomycin-resistant marker (MB231RN) were
surgically inoculated into the right inguinal mammary
gland fat pad of 4-week-old female NSG mice, followed
by primary tumor resection 4 weeks later, and lung
tissue was extracted at 9 weeks after cell inoculation as
shown in Figure 1A. The primary tumor and lung tis-
sues were digested and subjected to in vitro culture to
obtain the sublines MB231RN-MFP and MB231RN-LM,
representing tumor cells grown at the orthotopic site of
the mammary fat pad (MFP) or that spontaneously metas-
tasized to lung (LM), respectively. To compare the meta-
static potential of the sublines, cells (2.5 × 105/injection)
were inoculated into the right inguinal mammary gland
fat pad of 4-week-old female NSG mice, and the presence
of spontaneous metastatic foci in the lungs was examined
by histological analysis at 7 weeks posttransplant. Small
lung metastases (micrometastases) were observed in mice
inoculated with MB231RN-MFP cells (Figure 1B, top
panel). In contrast, large areas of lung parenchyma were
occupied by tumor cells (macrometaststases) in all mice
(n = 5) that received MB231RN-LM cells (Figure 1B,
middle panel). These results validate the enhanced lung
metastatic potential of the MB231RN-LM subline relative
to MB231RN parental cells or MB231RN-MFP cells.
Downregulation of microRNAs in MB231RN-LM cells
To identify miRNAs involved in metastasis, TaqMan-based
miRNA array analysis was performed using MB231RN,
MB231RN-LM and MB231RN-MFP cells. Among the 377
Figure 1 Identification of microRNAs associated with lung metastasis. (A) Flowchart outlining procedures used to establish sublines from
MB231RN, a MDA-MB-231 variant expressing red fluorescent protein (RFP) and a neomycin resistance marker. The MB231RN-LM subline was isolated
from spontaneous lung metastases, whereas the MB231RN-MFP subline was isolated from primary tumors grown in mammary fat pads (MFPs).
(B) Representative hematoxylin and eosin–stained lung sections from mice killed 7 weeks after tumor cell inoculation (2.5 × 105 cells/injection/mouse,
5 mice/group) are shown. (C) Fold changes of microRNAs (miRNAs) differentially expressed in MB231RN-LM cells compared to MB231RN-MFP cells
(gray bars) and parental MB231RN cells (black bars). The results are presented as mean ± SD (n = 3). (D) Expression of miR-18a and miR-17 in sublines
MB231RN-CE-MFP and MB231RN-CE-LM, which were generated from primary tumors (CE-MFP) or lung metastases (CE-LM) harvested from mice
inoculated with cells expanded from a single colony of the MB231RN line. Relative expression levels of miRNAs are presented as mean ± SD
(n = 3). *P < 0.05 by Student’s t-test. n, the number of experimental repeats.
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cantly deregulated in lung metastatic MB231RN-LM cells
in comparison to MB231RN or MB231RN-MFP cells (six
downregulated and four upregulated). The differential ex-
pression of these miRNAs was independently confirmed
by qPCR (Figure 1C). Notably, all of the downregulated
miRNAs in the MB231RN-LM cells are encoded by
MIR17HG. Examination of unprocessed transcripts
showed that the expressed level of pri-MIR17HG was sig-
nificantly reduced in MB231RN-LM cells compared to
MB231RN-MFP cells (the number of experimental re-
peats = 3, FC = 1.54, P < 0.05). This result suggests that de-
regulation of miRNAs encoded by MIR17HG in
metastatic cells is due to reduced gene transcription rather
than to impaired miRNA processing.To rule out the possibility that the downregulation of
MIR17HG in lung metastatic cells resulted from selec-
tion of a clonal variant present in the pooled
MB231RN population that may intrinsically express
low levels of MIR17HG, we repeated the same in vivo
experiment using a subline derived from a single
MB231RN colony (MB231RN-CE). Tumor cells iso-
lated from spontaneous lung metastases (MB231RN-
CE-LM) and orthotopic primary tumors (MB231RN-
CE-MFP) using this clonally expanded line were
subjected to miRNA expression analysis. The expres-
sion of miR-18a, along with miR-17, was significantly
decreased in cells derived from lung metastases relative to
those derived from primary tumors (Figure 1D). This
result confirmed that MIR17HG downregulation is an
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rather than clonal selection.
miR-18a suppresses tumor growth and lung metastasis
in vivo
Compared to other MIR17HG family members, miR-18a
is understudied and its function in tumor cells is largely
undefined. The maturation of miR-18a, but not other
MIR17HG family members, has been reported to be spe-
cifically regulated by heterogeneous nuclear riboprotein
A1 (HNRNPA1), implicating tight control of miR-18a
abundance in human cells [21]. Therefore, we speculated
that miR-18a deregulation might directly impact cell
metastatic potential. To examine whether miR-18a regu-
lates primary tumor growth and metastasis, we used a len-
tiviral construct that encodes a miR-18a stem loop and
GFP to ectopically express miR-18a in MB231RN-LM
cells (LM-miR-18a). An approximately twofold increase of
miR-18a expression was detected by qPCR in the trans-
duced cells, in comparison to cells that were transduced
with a control vector expressing GFP only (LM-GFP)
(Figure 2A). Because translation inhibition mediated byFigure 2 Effects of ectopic microRNA-18a expression on gene express
microRNA-18a (miR-18a) in cells transduced with lentiviral vector expressin
cells transduced with lentiviral vector expressing GFP only (LM-GFP). (B) Eff
levels were examined by quantitative PCR (qPCR) and normalized to ACTB.
reduced by miR-18a expression (n = 3, P < 0.05 by Student’s t-test). (C) Effec
predicted target mRNAs. RISC binding was examined by AGO2 immunopre
as fold change enrichment (AGO2-IP vs control immunoglobulin G immunop
LM-miR-18a cells vs in control cells). (D) Growth curves of LM-miR-18a and LM
Kruskal-Wallis analysis of variance followed by Dunn’s multiple-comparisons temiRNAs is usually coupled with target mRNA degradation
[22], we performed qPCR to examine the mRNA levels of a
panel of predicted miR-18a targets to confirm that the
ectopically expressed miR-18a functions properly in the
transfected cells. Five predicted targets of miR-18a were
identified according to TargetScan [23], including con-
nective tissue growth factor (CTGF), tumor necrosis factor
α–induced protein 3 (TNFAIP3), high-mobility group 20B
(HMG20B), inositol polyphosphate phosphatase-like 1
(INPPL1) and HIF1A. As shown in Figure 2B, the expres-
sion levels of these five mRNAs that harbor conserved
binding sites with an exact match to positions 2 through 8
of miRNA-18a in 3′-UTR were significantly decreased (the
number of experimental repeats = 3; P < 0.05) in response to
ectopic miR-18a expression. We next examined the inter-
action of miR-18a targets with RNA-induced silencing com-
plex (RISC) by using AGO2 immunoprecipitation followed
by qPCR analysis. As shown in Figure 2C, ectopic miR-18a
expression significantly increased the amount of the target
mRNAs in AGO2 immunocomplexes. In contrast, AGO2
binding of B-cell translocation gene 2 (BTG2) and
eukaryotic translation initiation factor 4E binding protein 2ion and cell growth in MB231RN-LM cells. (A) Expression levels of
g miR-18a green fluorescent protein (GFP) (LM-miR-18a) and or control
ect of miR-18a on expression levels of predicted target mRNAs. mRNA
The expression levels of all the presented genes were significantly
t of miR-18a on RNA-induced silencing complex (RISC) binding of
cipitation (AGO2-IP) followed by RNA purification and qPCR, presented
recipitation). *P < 0.05 by Student’s t-test (fold enrichment of AGO2-IP in
-GFP cells. All results are presented as mean ± SD (n = 3). *P < 0.05 by
st).
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not affected by ectopic expression of miR-18a. Notably, ec-
topic miR-18a expression slightly increased the cell growth
rate in vitro (Figure 2D), which is in agreement with a previ-
ous report showing that miR-18a overexpression enhances
proliferation of K562 and hepatoma cells [24,25].
We next examined the effect of ectopic miR-18a ex-
pression on primary tumor growth in vivo. LM-miR-18a
and LM-GFP cells (2.5 × 105) were inoculated into the
fourth inguinal mammary gland fat pads of 4-week-old
NSG mice. All females developed palpable tumors withinFigure 3 Effects of ectopic microRNA-18a expression on primary tum
primary tumors generated from lung metastatic and green fluorescent pro
results are presented as mean ± SE (n = 10). *P < 0.05 by Kruskal-Wallis analy
(B) Wet weights of primary tumors that were surgically removed at either 4
of variance followed by Dunn’s multiple-comparisons test. (C) Expression leve
primary tumor tissues harvested 6 weeks after inoculation and subjected to q
presented as mean ± SD (n = 3). *P < 0.05 by Student’s t-test. (D) Spontaneou
protein (RFP)–expressing cells on the dorsal surface of the left lung lobe were im
*P < 0.05 by Mann-Whitney U test (n = 8). The presence of tumor cells in th
formalin-fixed lung sections (10 μM) and quantified by qPCR using the huma
U test (n = 8). (E) Growth curves of primary tumors and images of lung metas
(MB231-18aIN) and control cells expressing mCherry only (MB231-C). Tumor volum
cells on the dorsal surface of the left lung lobe were imaged using a fluorescence
was quantified by hAlu-qPCR. *P<0.05 by Mann-Whitney U test (n=7). n, the num2 weeks. Both the LM-miR-18a and LM-GFP tumors
exhibited similar growth rates until grown to a volume of
approximately 500 mm3 (Figure 3A and 3B). At this point
of tumor progression (day 35 posttransplant), we ob-
served slower growth of the tumors derived from LM-
miR-18a cells. The differences in tumor growth were con-
firmed by comparing end-stage tumor wet weight
(6 weeks after inoculation; Figure 3B). Sustained expres-
sion of miR-18a in end-stage LM-miR-18a tumors was
confirmed by qPCR (Figure 3C). These results suggest
that ectopic miR-18a expression does not impact tumoror growth and spontaneous lung metastasis. (A) Growth curves of
tein microRNA-18a cells (LM-miR-18a and LM-GFP, respectively). The
sis of variance followed by Dunn’s multiple-comparisons test.
weeks or 6 weeks postinoculation. *P < 0.05 by Kruskal-Wallis analysis
ls of miR-18a in end-stage primary tumors. Total RNA was prepared from
uantitative PCR (qPCR) analysis for miRNA expression. The results are
s lung metastasis from orthotopic sites. Metastatic foci of red fluorescent
aged and counted using a fluorescence microscope at × 10 magnification.
e lungs was visualized by hematoxylin and eosin (H&E) staining of
n-specific primers of Alu repeats (hAlu-qPCR). *P < 0.05 by Mann-Whitney
tasis generated from MDA-MB-231 sublines with low miR-18a activity
es are presented as mean± SE (n=14). Metastatic foci of mCherry-expressing
microscope at × 10 magnification. The presence of tumor cells in the lungs
ber of experimental repeats.
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tumor mass.
To examine the effect of ectopic miR-18a expression
on spontaneous lung metastasis, primary tumors were
surgically removed at 4 weeks after inoculation, when the
tumor sizes were equivalent (LM-GFP: 235 ± 75 mm3 vs
LM-miR-18a: 231 ± 84 mm3). Lung metastases were eval-
uated 5 weeks after primary tumor resection via gross
examination of the dorsal surface of the left lung lobes
under a fluorescence microscope, followed by examination
of H&E-stained tissue sections. The number of lung meta-
static foci in mice inoculated with LM-miR-18a cells was
significantly reduced compared to that of mice inoculated
with LM-GFP cells (Figure 3D). Likewise, the number of
tumor cells detected by qPCR using primers specific for
the human Alu sequence in the lungs of mice inoculated
with LM-miR-18a was reduced by about 60% compared to
lungs of mice inoculated with LM-GFP (3,877 ± 641.6
cells/mg vs 1,496.0 ± 208.8 cells/mg lung tissue, respect-
ively (n = 8) (Figure 3D). When inspecting tissue sections
(10 μm thick) from mice inoculated with LM-miR-18a
cells, we observed similar intensities of GFP (coexpressed
with miR-18a) in lung metastatic cells and primary tumor
cells, suggesting that the ectopically overexpressed miR-18a
was retained in lung metastases. Taken together, these re-
sults demonstrate that ectopic miR-18a expression reduced
spontaneous lung metastasis from the MFPs.
We next examined the effect of inhibiting miR-18a ex-
pression on spontaneous lung metastasis in MDA-MB-
231 cells. A lentiviral vector expressing miArrest inhibitor
of miR-18a and mCherry (HmiR-AN0255-AM03) was
used to establish the subline MB231-18aIN. In contrast to
ectopic miR-18a expression, which reduced late-stage
tumor growth and lung metastasis, miR-18a inhibition
enhanced late-stage tumor growth and substantially in-
creased spontaneous lung metastasis (Figure 3E). Spe-
cifically, miR-18a inhibition increased final tumor wet
weight by about 20% (MB231-18aIN: 1,012 ± 278 mg
(n = 14) vs MB231-C: 852 ± 230 mg (n = 14), P = 0.0743
by unpaired t-test with Welch’s correction, 6 weeks
posttransplant) and increased cell numbers in lung tissues
more than 10-flold as measured by hAlu-qPCR (MB231-
18aIN: 4,274 ± 1,978 cells/mg lung tissue (n = 7) vs
MB231-C: 294 ± 183 cells/mg lung tissue (n = 7); P < 0.001
by unpaired t-test with Welch’s correction).
miR-18a regulates HIF1α activity and cell response
to hypoxia
HIF1A activation by hypoxia has been identified as a key
event for continuous expansion of tumor mass and me-
tastasis by stimulating angiogenesis and activating the
expression of metastatic signature genes in various types
of tumor cells [18,26-28]. We identified an evolutionarily
conserved miR-18a target site located in the 3′-UTR ofHIF1A mRNA, consistent with observations that ectopic
miR-18a expression significantly increased HIF1A mRNA
interaction with RISC (Figure 2B). Therefore, we hypothe-
sized that miR-18a might affect tumor growth and metas-
tasis by targeting HIF1A.
First, we examined whether miR-18a targets HIF1A
mRNA through the conserved binding site located in
the 3′-UTR using a MDA-MB-231/DROSHA-shRNA
subline that is defective in miRNA synthesis [16] and a
HIF1A-3′-UTR-Luc reporter. As shown in Figure 4A
(left panel), HIF1A-3′-UTR-Luc activity in cells cotrans-
fected with pEZX-MR06 (expressing miR-18a and GFP)
was significantly decreased in comparison to cells
cotransfected with a control vector (expressing GFP
only). Point mutations or deletion of the miR-18a target
site (GCACCUU, positions 409 to 415 of the HIF1A
3′-UTR) abolished the inhibitory effect of miR-18a on
reporter luciferase expression.
We next compared HIF1A protein expression in cells
cultured under normoxia or hypoxia (2% O2 for 16 hours)
using a cell-based ELISA that measures total HIF1A pro-
tein levels in the context of whole cells (Figure 4B). HIF1A
protein levels in LM-GFP cells were increased about six-
fold in response to hypoxia. LM-miR-18a cells expressed
lower levels of HIF1A protein than LM-GFP cells at either
normoxia or hypoxia. In agreement with the reduced
HIF1A expression, reduced hypoxia induction of a panel
of known hypoxia responsive genes was reduced in
LM-miR-18a cells, including PFKBP3 and BHLHE40,
which were also confirmed at the protein level by
Western blotting (Figure 4B).
To examine the consequence of HIF1A reduction by
miR-18a on cell growth under hypoxia, alone or in com-
bination with acidosis, environments that are frequently
encountered by cells within solid tumors, we measured
viable cell numbers after growing cells under hypoxia
(2% O2) with or without exposure to a high concentration
of lactic acid (25 mM) for 48 hours. Ectopic miR-18a ex-
pression significantly decreased viable cell numbers when
cells were exposed to hypoxia alone or to hypoxia in com-
bination with lactic acidosis (Figure 4C).
To obtain a more global and unbiased characterization
of the effect of miR-18a on HIF1A activity, we compared
gene expression profiles of LM-GFP and LM-miR-18a
cells treated with CoCl2, a hypoxia mimetic that rapidly
stabilizes HIF1A protein by inhibiting its prolyl hydrox-
ylation [29,30]. After exposure to CoCl2 (200 μM for
4 hours), 219 or 132 genes were found to be significantly
upregulated or downregulated, respectively, in LM-GFP
cells (FDR = 0.1, FC > 1.5). All data are reported in the
GEO database [GEO:GSE45362]. Consistent with miR-
18a-mediated suppression of HIF1A, a smaller number
of genes were found to change in response to CoCl2
treatment in LM-miR-18a cells, with 164 and 122 genes
Figure 4 Effects of microRNA-18a on hypoxia-inducible factor 1α expression and hypoxic response. (A) MicroRNA-18a (miR-18a) directly
targeted the 3′ untranslated region (3′-UTR) of hypoxia-inducible factor 1α (HIF1A) mRNA and ectopic miR-18a expression decreased HIF1A protein
levels in MB231RN-LM cells cultured at either normoxia or hypoxia (2% O2 for 16 hours). HIF1A-3′-UTR-Luciferase reporter activities were measured in
MDA-MB-231/DROSHA-shRNA cells cotransfected with either pEZX-MR06 (expressing miR-18a) or control vector pEZX-GFP. GFP, Green fluorescent
protein; shRNA, Short-hairpin RNA. Luciferase activities were normalized to internal control pSV-β-galactosidase and are presented as mean ± SD.
*P < 0.05 by Student’s t-test (n = 4). WT, mutant and deletion represent wild type, miR-18a binding site mutation and miR-18a binding site
deletion of HIF1A-3′-UTR-Luciferase reporter, respectively. HIF1A protein levels in MB231RN-LM cells transduced with miR-18a or GFP were measured
by a cell-based enzyme-linked immunosorbent assay, normalized to cytochrome c and presented as mean ± SD (n = 4). *P < 0.05 by Student’s t-test.
(B) miR-18a attenuated the induction of HIF1A target genes by hypoxia in MB231RN-LM cells. Cells were exposed to hypoxia (2% O2 for 16 hours).
mRNA levels were measured by quantitative PCR and normalized to ACTB, and data are presented as mean± SD (n= 3). The inset shows the expression levels
of indicated proteins in nuclear extracts (NEs) or whole-cell lysates (WCEs) detected by immunoblotting. TATA-binding protein (TBP) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) were used as loading controls for NEs and WCEs, respectively. (C) Ectopic miR-18a expression in MB231RN-LM cells
reduced viable cell numbers after cells were exposure to hypoxia (2% O2) and lactic acidosis (25 mM lactic acid, pH 6.7) for 48 hours. *P< 0.05 by Student’s
t-test. n, the number of experimental repeats.
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Ingenuity Pathway Analysis revealed that several signal-
ing pathways were differentially affected by CoCl2 in
LM-GFP and LM-miR18a cells (Figure 5B). For example,
CoCl2-induced genes in LM-GFP cells were significantly
enriched for HIF1A, granulocyte-macrophage colony-
stimulating factor and hepatocyte growth factor signaling
pathways, indicating activation of HIF1A and downstream
angiogenic signaling pathways. CoCl2-downregulated genes
in LM-GFP cells were significantly enriched in the integrin,
paxillin and integrin-linked kinase signaling pathways
involved in cell adhesion and migration. In contrast, in LM-
miR-18a cells, none of these known HIF1A regulated path-
ways were significantly affected by CoCl2 exposure. Taken
together, these observations provide additional evidence in
support of an essential role for miR-18a in regulating HIF1A
activity in breast tumors. Notably, according to three targetprediction programs (TargetScan, PicTar and miRBase), most
of the CoCl2-responsive genes affected by miR-18a lack target
sites of miR-18a, suggesting that miR-18a regulates CoCl2
-responsive genes primarily through indirect mechanisms.
To investigate whether miR-18a-mediated HIF1A inhib-
ition can be extended to other basal-like breast cancer cell
lines, we examined the impact of ectopic miR-18a expres-
sion in MDA-MB-436 cells. As shown in Figure 6, miR-18a
expression downregulated the expression of HIF1A protein
as well as the induction of HIF1A target genes at hypoxia.
In addition, ectopic miR-18a expression in MDA-MB-436
cells significantly decreased cell growth under hypoxia
(Figure 6C) and abolished hypoxia-induced cell invasion
(Figure 6D). Taken together, these observations provide
additional evidence that supports a conserved role for
miR-18a in limiting HIF1A activity in basal-like breast can-
cer cells.
Figure 5 Ectopic microRNA-18a expression modified gene expression profiles of MB231RN-LM cells in response to CoCl2 treatment
(200 μM for 4 hours). (A) Venn diagrams of cobalt(II) chloride (CoCl2)–regulated genes (fold change≥ 1.5, CoCl2 () vs untreated, false discovery
rate = 0.1) in LM-miR-18a and LM-GFP cells. GFP, Green fluorescent protein; miR-18a, MicroRNA-18a. (B) Signaling pathways differentially affected by
CoCl2 in LM-miR-18a and LM-GFP cells. Enriched signaling pathways of CoCl2-regualted genes were identified using Ingenuity Pathway Analysis
software. AMPK, 5′ adenosine monophosphate-activated protein kinase; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HGF,
Hepatocyte growth factor; HIF1A, Hypoxia-inducible factor 1α; ILK, Integrin-linked kinase; mTOR, Mammalian target of rapamycin.
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primarily through hypoxia-inducible factor 1α
In cultured cells, miR-18a inhibition enhanced gene
expression induced by hypoxia (2% O2 for 6 hours)
(Figure 7A). Immunoblotting assay results showed that
miR-18a inhibition increased baseline protein levels of
HIF1A (Figure 7B, left panel). Consistent with the obser-
vation that miR-18a inhibition promoted tumor growth
and metastasis in vivo (Figure 3E), MB231-18aIN cells
were more resistant to anoikis (Figure 7C) and more in-
vasive (Figure 7D) in comparison to control MB231-C
cells. To confirm that these cellular changes induced by
miR-18a inhibition were mediated by HIF1A, we examined
the impact of HIF1A knockdown on the efficacy of a
miR-18a inhibitor. Expression of HIF1A shRNA in
MB231-C or MB231-18aIN cells reduced HIF1A mRNA
levels by approximately 70% compared to control cells
transduced with empty vector (Figure 7A). The reduced
HIF1A expression in MB231-18aIN-HIF1AshRNA cells
compared to MB231-18aIN-Vec cells was also confirmed
by Western blotting (Figure 7B, right panel). HIF1A
knockdown substantially decreased hypoxia-induced
gene expression in both MB231-C and MB231-18aIN cells
(Figure 7A), including PFKFB3, BHLHE40, angiopoietin-
like 4 (ANGPTL4) and integrin α5 (ITGA5). Consistent
with the known function of HIF1A to protect cells againstanoikis and promote cell invasion, HIF1A knockdown
substantially reduced the viability of cells cultured in
suspension as well as cell invasive activity (Figure 7C
and 7D). Importantly, no difference in cell viability was
observed in suspension culture or in cell invasion be-
tween MB231-C-shHIF1A and MB231-18aIN-shHIF1A
cells, demonstrating that the predominant target of miR-
18a that mediates phenotypes in MDA-MB-231 cells is
HIF1A.
Ectopic HIF1A expression in MDA-MB-231 cells was
previously reported to suppress tumor growth in a
xenograft model [29]. Therefore, it is difficult to rescue
a miR-18a-mediated suppressive effect on tumor growth
and metastasis by ectopic HIF1A expression in LM-miR-
18a cells. To provide further evidence that miR-18a regu-
lates HIF1A activity, we examined the effect of ectopic
miR-18a-5p (miR-18a) expression on hypoxia-induced
tumorigenic activity of MCF7 cells. In an orthotopic
xenograft model, MCF7 cells (1 × 106 cells/injection)
generated small tumors with a latency period of ap-
proximately 7 weeks. Prolonged exposure of MCF7
cells to hypoxia (2% O2 for 4 weeks in vitro) prior to
inoculation substantially reduced the latency period of
tumor initiation and enhanced tumor growth. Ectopic
miR-18a expression in MCF7 cells reduced HIF1A protein
expression (Figure 8A), dampened hypoxia-induced gene
Figure 6 Effects of microRNA-18a on hypoxia-inducible factor 1α expression and hypoxia response in MDA-MB-436 cells. (A) Ectopic
microRNA-18a (miR-18a) expression decreased hypoxia-inducible factor 1α (HIF1A) protein levels in cells cultured under normoxia or hypoxia (2%
O2 for 16 hours). HIF1A protein levels were measured using a cell-based enzyme-linked immunosorbent assay and normalized to cytochrome c.
The data are presented as mean ± SD (n = 4). *P < 0.05 by Student’s t-test. GFP, Green fluorescent protein. (B) miR-18a attenuated hypoxic gene
expression. Cells were exposed to hypoxia (2% O2 for 16 hours), and mRNA levels were measured by quantitative PCR and normalized to ACTB.
Data are presented as mean ± SD (n = 3). (C) Ectopic miR-18a expression reduced viable cell numbers in cells exposed to hypoxia (2% O2 for
72 hours). *P < 0.05 by Student’s t-test. (D) Ectopic miR-18a expression inhibited cell invasion under normoxia and abolished hypoxia-induced cell
invasion. The results are presented as mean ± SD (n = 6). *P < 0.05 by Student’s t-test. n, the number of experimental repeats.
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induced tumorigenic activity (Figure 8C). These results
provide additional evidence supporting a role for miR-18a
in regulating hypoxic response in breast cancer cells.
Reverse correlation of miR-18a expression with expression of
HIF1A and panel of hypoxia-responsive genes in basal-like
breast tumors
To examine the clinical relevance of miR-18a mediated
HIF1A inhibition, we investigated the relationship be-
tween miR-18a and HIF1A mRNA levels in human
breast tumor specimens by analyzing four data sets that
contain both mRNA and miRNA expression data, which
are available from TCGA or in the GEO database [GEO:
GSE19783, GEO:GSE22220, GEO:GSE28884] [30-33].
The expression of miR-18a, along with other MIR17HG
family members, was higher in basal-like tumors than in
the other molecular subtypes defined by the PAM50
classifier [19] (Figure 9A, left panel). HIF1A mRNA is
highly expressed in both basal and ERBB2 subtypes com-
pared to luminal subtypes (Figure 9A, right panel), inagreement with the observation that HIF1A protein is
expressed at higher levels in basal cancers relative to lu-
minal cancers [34]. Within the basal-like breast tumors,
we found a significant inverse correlation between the ex-
pression levels of miR-18a and HIF1A mRNA in all four
data sets (Figure 9B). This correlation was not detected
for any other subtype of breast cancer. These results im-
plicate a role for miR-18a in restraining HIF1A activity in
basal-like breast tumors.
We further examined the correlation of the expression
levels of miR-18a and hypoxia-responsive genes that were
associated with distant metastasis of breast tumors. The
hypoxia-responsive genes in basal-like breast cancer cells
were retrieved from GEO data sets [GEO:GSE17188,
GEO:GSE18494] [28,35]. The correlation of hypoxia-re-
sponsive gene expression with DMFS interval was
assessed using the GOBO algorithm, which analyzes the
correlation of gene expression and clinicopathological
characteristics using expression data of 1,881 breast tumor
specimens annotated with clinical information [33]. A
panel of hypoxia-responsive genes was found to be
Figure 7 HIF1A knockdown abolished the effect of microRNA-18a on cell metastatic properties. (A) Expression fold changes of hypoxia-inducible
factor α (HIF1A) and hypoxia-responsive genes in MDA-MB-231 cells expressing microRNA-18a (miR-18a) inhibitor and/or HIF1A short-hairpin RNA (shRNA).
The mRNA levels were measured by quantitative PCR after cells were exposed to hypoxia (2% O2 for 6 hours) and normalized to ACTB. Data are presented
as mean ± SD (n= 3). (B) HIF1A protein expression levels in nuclear extracts from untreated or hypoxia-treated (2% O2 for 6 hours) cells were detected by
immunoblotting assay. TATA-binding protein (TBP) was used as a loading control. (C) Effect of miR-18a inhibitor and HIF1A shRNA on viability of cells
cultured in suspension for 6 days. (D) Effect of miR-18a inhibitor and HIF1A shRNA on cell invasion. The results are presented as mean ± SD (n = 4).
*P < 0.05 by Student’s t-test. n, the number of experimental repeats.
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basal-like tumors (P < 0.05 by Kaplan-Meier analysis
with 10-year censoring). We examined their correlation
with miR-18a expression in the above-mentioned four
data sets, which contain both mRNA and miRNA ex-
pression data. This analysis led to the identification of a
panel of metastasis-associated hypoxic genes that nega-
tively correlated with miR-18a (Figure 9C). The individ-
ual or collective roles of these genes in mediating the
miR-18a-dependent suppression of lung metastasis in
basal breast cancers warrant further studies.
Discussion
Deregulation of MIR17HG has been linked to breast
cancer progression, but the function of each individual
miRNA encoded by MIR17HG in breast tumor cells has
not yet been fully defined [9,12,36-38]. Compared to other
family members of MIR17HG, miR-18a is less studied,
and only limited information is available regarding its
function in human cancer cells. Regarding luminal breast
cancer cells, miR-18 has been shown to inhibit cell prolif-
eration by targeting ESR1 [11]. In glioblastomas, miR-18a
has been reported to repress tumor progression throughtargeting SMAD3 and CTGF [39]. Here we report evi-
dence that miR-18a plays an important role in restricting
tumor growth and pulmonary metastasis of basal-like
breast cancer by regulating HIF1A expression and hypoxic
response. HIF1A was reported as a target of MIR17HG
in lung cancer cells, but the specific role of miR-18a in
the control of HIF1A expression and activity was not
tested [40].
We found that miR-18a, along with other family mem-
bers encoded by MIR17HG, was downregulated in breast
cancer cells that spontaneously metastasized to lungs in
an orthotopic xenograft model. We further confirmed that
MIR17HG downregulation is an acquired trait associated
with spontaneous lung metastasis by using orthotopic
xenograft models derived from cell colony expansion. This
finding is in line with the previous observation that
MIR17HG expression is downregulated in human primary
breast tumors with positive lymph node metastasis com-
pared to those with no metastasis [12]. MIR17HG down-
regulation during metastatic progression is also congruent
with the reported inverse correlation between expression
of miR-92a, another member encoded by MIR17HG, and
the tumor grade and recurrence-free survival of breast
Figure 8 Ectopic microRNA-18a expression diminished hypoxia induced tumorigenic activity of MCF7 cells. (A) MicroRNA-18a (miR-18a)
expression in MCF7 cells reduced hypoxia-inducible factor 1α (HIF1A) protein expression as measured using a cell-based enzyme-linked immunosorbent
assay. GFP, Green fluorescent protein. *P < 0.05 by Student’s t-test. (B) miR-18a expression dampened hypoxia-induced gene expression in MCF7 cells.
Gene mRNA levels were determined by quantitative PCR and normalized to ACTB. (C) Exposure to hypoxia (2% O2 for 4 weeks) prior to inoculation
increased tumorigenic activity of MCF7 cells. The hypoxia-induced tumorigenic activity was abolished by ectopic miR-18a expression.
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sion was not recognized in a previous study on lung
metastatic derivatives of MDA-MB-231 cells [41]. The
discrepancy could be caused by differences in experi-
mental approach, including the use of different mouse
strains and different inoculation routes of tumor cells
than those we employed in our present study.
The results of our in vivo studies with orthotopic
xenograft models of the metastatic MDA-MB-231 variant
demonstrate that ectopic miR-18a expression significantly
attenuated continuous expansion of primary tumor mass
and decreased spontaneous lung metastasis. In contrast,
miR-18a inhibition increased primary tumor growth and
lung metastasis. These observations support a role of
miR-18a in repressing tumor mass expansion and distant
metastasis. Cells in solid tumors commonly encounter
fluctuations in nutrient and oxygen availability caused
by unbalanced cell proliferation and blood vessel devel-
opment [26]. Continuous tumor growth is dependent
on adaptation of tumor cells to hypoxic stresses and
angiogenesis, two processes that are primarily regulated
by HIF1A [42]. In addition, mounting evidence suggests
a critical role of hypoxia in promoting tumor metastatic
progression by rendering cells resistant to apoptosis andinvasive features. The results of our mechanistic studies
provide evidence that miR-18a directly regulates HIF1A
expression and consequently the expression of hypoxia-
responsive genes and cell response to hypoxia.
Expression data analysis using a metadata set composed
of data from 1,881 breast tumors [20] revealed that higher
expression of HIF1A and a panel of hypoxia-responsive
genes is associated with shorter DMFS interval of patients
with basal-like tumors, but not other subtypes. This find-
ing is in agreement with previous reports that enhanced
hypoxic response is associated with poor prognosis and
chemotherapy resistance of basal-like tumors [43,44]
and supports the notion that HIF1A activation drives
metastatic progression of basal-like tumors. Importantly,
on the basis of four independent data sets containing both
miRNA and mRNA expression data, we found that miR-
18a expression is inversely correlated with the expression
of HIF1A and hypoxia-responsive genes in basal-like tu-
mors. However, the available samples of basal-like tumors
with both miRNA expression and DMFS data are not
sufficient to establish the prognostic value of miR-18a for
distant metastasis. Taken together, our observations
suggest a role of miR-18a in suppressing metastasis by
restricting hypoxic response in basal-like breast tumors.
Figure 9 Correlation of microRNA-18a expression with HIF1A mRNA expression, hypoxia-responsive gene expression and distant
metastasis in breast tumors. (A) Differential expression of microRNA-18a (miR-18a) and hypoxia-inducible factor 1α (HIF1A) mRNA in breast cancer
subtypes. Expression data were retrieved from the Cancer Genome Atlas database. GE, Generalized estimating equation. (B) There was an inverse
correlation between miR-18a and HIF1A mRNA expression in basal-like breast tumors. The basal-like breast tumors in four individual data sets were
defined according to the PAM50 classifier. (C) Higher expression of HIF1A and hypoxia-responsive genes is associated with a shorter interval of
distant metastasis–free survival (DMFS) of patients with basal-like breast tumors. Kaplan-Meier analysis was conducted using the GOBO program.
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tion rates and rapid mass expansion, which lead to cyclic
hypoxia and reoxygenation. Fine-tuned HIF1A activity
by miR-18a may represent an essential mechanism to
balance cell proliferation, survival and metastasis. In
general, activation of HIF1A and hypoxia-responsive
genes puts tumor cells in a survival and invasive state
with reduced proliferation [45-48]. High expression of
miR-18a in basal-like tumors (Figure 9A) may play a role
in promoting cell growth when oxygen supply becomes
abundant by restricting the antiproliferative activity of
the HIF1A signaling pathway. This notion is consistent
with previously report findings that tumors derived from
transformed HIF1A−/− astrocytes grew faster than its
HIF1A+/+ counterpart when placed in the vascular-rich
brain parenchyma [49]. However, cells under hypoxicstress rely on enhanced HIF1A activation to survive and
obtain invasive features. Constitutive high miR-18a expres-
sion might be detrimental to tumor mass expansion and
metastatic progression by restraining hypoxic response
and consequently deterring hypoxia-induced apoptotic re-
sistance and invasion.
The outcome of hypoxia-induced HIF1A activation was
shown to be cell context– and tumor microenvironment–
dependent [47,49]. As an upstream regulator of HIF1A,
miR-18a function is likely tumor type–dependent. This
notion is in line with previously reported findings that
miRNAs encoded by MIR17HG promote development of
B-cell lymphomas and lung cancer, but repress glioblast-
oma progression [38]. On the basis of our study results,
we cannot exclude the possibility that other targets may
contribute to miR-18a-mediated suppression on tumor
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http://breast-cancer-research.com/content/16/4/R78growth and metastasis. By integrated analysis of genes reg-
ulated by miR-18a under normoxia using a data set from
this study [GEO:GSE45362], miRNA target sites, expres-
sion correlation of mRNA and miRNA, and correlation
with DMFS of patients with basal-like breast tumors, we
discovered that miR-18a potentially targets the prometa-
static gene matrix metallopeptidase 3 (MMP3). Since
MMP3 is a hypoxia-responsive gene, miR-18a may modify
the outcome of hypoxia by modulating the expression of
specific hypoxia-responsive genes in addition to a general
attenuation of hypoxic response by directly targeting
HIF1A. It remains to be determined whether MMP3
downregulation contributes to miR-18a-mediated me-
tastasis suppression.
Conclusions
The results of this study reveal a novel role for miR-18a
in repressing metastasis of basal-like breast tumors by
restricting HIF1A activity and regulating cell responses to
hypoxia. The inverse correlation between miR-18a and
HIF1A and hypoxia signature genes in basal-like breast
tumors is significant in clinical samples and is consistent
across multiple data sets. However, understanding how
fluctuating miR-18a and HIF1A levels ultimately drive
metastasis from the primary tumor to reduce survival
requires further investigation.
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